Կանադա - անգլերեն - Health Canada

merck canada inc - levodopa; carbidopa - tablet (extended-release) - 100mg; 25mg - levodopa 100mg; carbidopa 25mg - dopamine precursors

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg); levodopa, quantity: 200 mg - tablet, modified release - excipient ingredients: hyprolose; magnesium stearate; ferric oxide; va/crotonates copolymer; quinoline yellow aluminium lake - idiopathic parkinsonism, where standard formulations containing levodopa/carbidopa have produced inadequate control. experience is limited with sinemet cr 200/50 in patients who have not been treated with levodopa before.

Կանադա - անգլերեն - Health Canada

organon canada inc. - carbidopa; levodopa - tablet - 25mg; 250mg - carbidopa 25mg; levodopa 250mg - dopamine precursors

Կանադա - անգլերեն - Health Canada

apotex inc - carbidopa; levodopa - tablet - 25mg; 100mg - carbidopa 25mg; levodopa 100mg - dopamine precursors

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - carbidopa monohydrate; levodopa - oral tablet - 12.5mg ; 50mg

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - carbidopa levodopa - tablets - 25/250 milligram

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

clear pharmacy - levodopa, carbidopa - tablets - 25/100 milligram - dopa and dopa derivatives

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - carbidopa levodopa - tablets - 12.5/50 milligram

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - carbidopa; levodopa - tablet - 12.5 mg/50 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

merck sharp & dohme corp. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - sinemet cr is indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with sinemet cr. these inhibitors must be discontinued at least two weeks prior to initiating therapy with sinemet cr. sinemet cr may be administered concomitantly with the manufacturer's recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hcl) (see precautions, drug interactions). sinemet cr is contraindicated in patients with known hypersensitivity to any component of this drug, and in patients with narrow-angle glaucoma.